Releases Geral
BioPharmaSpec Announces Major Investments in Mass Spectrometry and Related Instrumentation
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 3 de junho de 2024
BioPharmaSpec
MALVERN, Pa. and ST. SAVIOUR, Jersey, June 03, 2024 (GLOBE NEWSWIRE) — BioPharmaSpec (BioPharmaSpec), the leading global Contract Research Organization (CRO) for discovery and preclinical characterization of biopharmaceuticals, has made major new investments in instrumentation, including top-of-the-range Mass Spectrometers, to support its clients in their product development goals.
On June 1st, 2024, BioPharmaSpec announced that it had recently purchased a range of new Mass Spectrometry instrumentation, including: Waters Select Series CYCLIC Ion Mobility Separation (IMS) High Definition LC-MS/MS with ECD, SCIEX ZenoTOF 7600 LC-MS/MS with EAD, Waters Xevo TQ Absolute and Waters Xevo G3 LC-MS/MS Q-TOFs.
To further support Clients with the provision of their first-class characterization services, BioPharmaSpec has also expanded its overall analytical instrumentation portfolio with the Bio-Techne (Protein Simple) Maurice Flex icIEF, CE-SDS and cIEF instrument, two Shimadzu PPSQ-53A Gas Phase Sequencers and a Wyatt DAWN Ambient 18 angle Multi Angle Light Scattering with Integrated DLS and Optilab dRI detector.
The instruments currently being installed and qualified across BioPharmaSpecs global laboratories further enhance BioPharmaSpecs already impressive mass spectrometric, chromatographic and spectroscopic service provision.
About BioPharmaSpec
BioPharmaSpec is a CRO specializing in the structural characterization and physicochemical analysis of recombinant biopharmaceuticals, including biosimilars and biobetters, monoclonal antibodies, Antibody Drug Conjugates (ADCs), gene therapy products (i.e. AAV- based therapies), peptides, oligonucleotides and many more product types, with a focus on discovery, early and pre-clinical phases.
Contact:
Lindsay McGowan, Director of Business Development, BioPharmaSpec
Email: l.mcgowan@biopharmaspec.com
For more information, visit https://biopharmaspec.com/
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral King Faisal Specialist Hospital & Research Centre Conclui com Sucesso sua Participação Como Parceiro Estratégico de Saúde na Global Health Exhibition 2023
7 de novembro de 2023King Faisal Specialist Hospital & Research Centre RIADE, Arábia Saudita, Nov. 07, 2023 (GLOBE NEWSWIRE) — A Global Health Exhibition, realizada de 29 a 31 de outubro de 2023, foi um sucesso
Saiba Mais -
Releases Geral Tealiums Digital Velocity conferences return globally
4 de junho de 2024San Diego, June 04, 2024 (GLOBE NEWSWIRE) -- Tealium, the largest independent and most trusted customer data platform (CDP), is hosting three flagship Digital Velocity c
Saiba Mais -
Releases Geral Hoff Analytics participará pela primeira vez da Agrishow
8 de maio de 2024Sorocaba, SP--(DINO - 03 mai, 2024) - Entre 29 de abril a 03 de maio, acontece em Ribeirão Preto -SP a 29ª edição do AgriShow, uma feira agrícola
Saiba Mais